Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
Settings
RNN Rexahn Pharmaceuticals, Inc. daily Stock Chart
RNN [AMEX]
Rexahn Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.08 Insider Own4.19% Shs Outstand197.22M Perf Week0.53%
Market Cap71.33M Forward P/E- EPS next Y-0.05 Insider Trans0.00% Shs Float189.84M Perf Month-0.63%
Income-13.70M PEG- EPS next Q-0.03 Inst Own11.90% Short Float0.90% Perf Quarter-25.42%
Sales- P/S- EPS this Y-57.10% Inst Trans168.00% Short Ratio3.60 Perf Half Y-33.75%
Book/sh0.10 P/B3.62 EPS next Y44.40% ROA-47.90% Target Price2.83 Perf Year-51.12%
Cash/sh0.11 P/C3.32 EPS next 5Y- ROE-61.50% 52W Range0.26 - 0.85 Perf YTD-0.36%
Dividend- P/FCF- EPS past 5Y-17.10% ROI- 52W High-57.45% Beta0.23
Dividend %- Quick Ratio7.20 Sales past 5Y- Gross Margin- 52W Low39.12% ATR0.03
Employees22 Current Ratio7.20 Sales Q/Q- Oper. Margin- RSI (14)51.21 Volatility7.56% 9.79%
OptionableNo Debt/Eq0.00 EPS Q/Q-100.00% Profit Margin- Rel Volume0.52 Prev Close0.37
ShortableYes LT Debt/Eq0.00 EarningsFeb 09 AMC Payout- Avg Volume477.59K Price0.36
Recom1.70 SMA207.89% SMA50-4.83% SMA200-32.16% Volume250,600 Change-2.43%
Mar-20-15Initiated MLV & Co Buy $1.25
Dec-28-12Initiated Burrill Institutional Research Mkt Outperform $1
Jan-18-12Resumed Rodman & Renshaw Mkt Perform
Jun-16-11Resumed Brean Murray Buy $3
Dec-02-10Initiated Brean Murray Buy $3
Feb-01-16 09:31AM  Rexahn Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016 at noodls +5.59%
09:00AM  Rexahn Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016 GlobeNewswire
Jan-25-16 09:17AM  Rexahn Pharmaceuticals Announces Supinoxin Poster Presentations at the 2016 Gastrointestinal Cancers Symposium at noodls
09:00AM  Rexahn Pharmaceuticals Announces Supinoxin Poster Presentations at the 2016 Gastrointestinal Cancers Symposium GlobeNewswire
Jan-22-16 09:00AM  BioWatch News' Alan Leong Interviewed by The Life Sciences Report Marketwired +11.41%
Jan-12-16 09:00AM  New Preclinical Data for Supinoxin Show Oral Administration Produces Clinically Meaningful Tumor Growth Inhibition GlobeNewswire
Jan-11-16 09:00AM  Rexahn Pharmaceuticals Archexin® Shows Dose-Dependent Tumor Reduction in a Phase IIa Clinical Study GlobeNewswire
Jan-05-16 09:00AM  Rexahn Pharmaceuticals to Present at Biotech Showcase 2016 GlobeNewswire
Dec-18-15 09:00AM  BioNap Consulting's Jason Napodano Interviewed by The Life Sciences Report Marketwired -9.76%
Dec-14-15 09:00AM  Rexahn Pharmaceuticals Announces New Data for Supinoxin Showing Potent Tumor Growth Inhibition GlobeNewswire
Dec-08-15 01:16PM  REXAHN PHARMACEUTICALS, INC. Financials
Nov-23-15 03:07PM  Biotechs Under 20 Dollars Poised to Breakout Accesswire +5.41%
Nov-12-15 05:12PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Nov-11-15 09:00AM  Rexahn Pharmaceuticals to Present at the Stifel 2015 Healthcare Conference on November 18, 2015 GlobeNewswire
Nov-06-15 09:09AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement -11.69%
09:00AM  Rexahn Announces $7.0 Million Registered Direct Offering GlobeNewswire
Nov-05-15 09:07AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
09:00AM  Rexahn Pharmaceuticals Reports Interim Clinical Data for Archexin® at the 14th International Kidney Cancer Symposium GlobeNewswire
Nov-04-15 07:47AM  4 Stocks Under $10 Making Big Up Moves on Big Volume at TheStreet
Nov-03-15 09:37AM  Rexahn reports 3Q loss +8.38%
09:00AM  Rexahn Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update GlobeNewswire
Nov-02-15 04:46PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
Oct-26-15 09:13AM  Rexahn Pharmaceuticals Receives U.S. Patent for RX-3117 Anti-Cancer Program GlobeNewswire
Oct-14-15 09:00AM  Rexahn Pharmaceuticals to Present at the 14th Annual BIO Investor Forum GlobeNewswire
Sep-30-15 09:00AM  Rexahn's Human Data Confirms Anti-Cancer Advantage Accesswire
Sep-28-15 09:13AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -13.11%
09:00AM  Rexahn Pharmaceuticals Presents Preliminary Clinical Data for Supinoxin(TM) and RX-3117 Oncology Programs at the European Cancer Congress 2015 GlobeNewswire
Sep-25-15 09:00AM  Rexahn Pharmaceuticals to Present Preliminary Clinical Data at the European Cancer Congress 2015 GlobeNewswire
Sep-23-15 09:00AM  Rexahn Pharmaceuticals to Present at the 15th Annual Biotech in Europe Investor Forum GlobeNewswire
Sep-10-15 09:01AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Sep-08-15 09:01AM  Rexahn Pharmaceuticals to Present at the Biopharm America(TM) 2015 Conference in Boston GlobeNewswire
Aug-31-15 09:00AM  Rexahn Pharmaceuticals to Present at the 17th Annual Rodman and Renshaw Global Investment Conference on September 10, 2015 GlobeNewswire
Aug-10-15 09:24AM  Rexahn reports 2Q loss
09:00AM  Rexahn Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Corporate Update GlobeNewswire
Aug-09-15 08:13PM  10-Q for Rexahn Pharmaceuticals, Inc. at Company Spotlight
Aug-07-15 06:16PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
Jul-17-15 04:13PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jul-14-15 09:02AM  Rexahn Pharmaceuticals Awarded Patent in Japan for Novel Targeted Cancer Drug Delivery Platform GlobeNewswire +10.91%
Jun-22-15 09:00AM  Rexahn Announces the Appointment of Peter Brandt as Chairman of the Board GlobeNewswire
Jun-09-15 09:00AM  Data on Rexahns RX-3117 in Non-Small Cell Lung Cancer Presented at 16th International Symposium of the Purine and Pyrimidine Society GlobeNewswire
Jun-08-15 09:00AM  National Cancer Institute Accepts Rexahn's RX-21101 for Its Nanotechnology Characterization Laboratory's Preclinical Characterization Program GlobeNewswire
Jun-05-15 04:20PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
May-29-15 08:51AM  5 Stocks Under $10 Ready to Spike Higher at TheStreet
May-28-15 09:00AM  Strong Data on Rexahn's Non-Toxic Targeted Therapy Revealed at Top Cancer Meetings Accesswire
May-13-15 05:01PM  Rexahn Announces Poster Presentations at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-11-15 09:00AM  Rexahn Pharmaceuticals Reports First Quarter 2015 Financial Results and Pipeline Update GlobeNewswire
May-10-15 08:11PM  10-Q for Rexahn Pharmaceuticals, Inc. at Company Spotlight
May-08-15 04:49PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
May-04-15 08:12PM  10-K for Rexahn Pharmaceuticals, Inc. at Company Spotlight
Apr-21-15 09:12AM  New Data Show Rexahn's Supinoxin(TM) Decreases the Migration of Human Triple Negative Breast Cancer Cells in a Metastatic Cancer Model at noodls
09:00AM  New Data Show Rexahn's Supinoxin(TM) Decreases the Migration of Human Triple Negative Breast Cancer Cells in a Metastatic Cancer Model GlobeNewswire
Apr-20-15 09:40AM  Rexahn Identifies RX-3117 Biomarker & Presents Data at the 2015 American Association for Cancer Research Annual Meeting at noodls
09:00AM  Rexahn Identifies RX-3117 Biomarker & Presents Data at the 2015 American Association for Cancer Research Annual Meeting GlobeNewswire
Apr-13-15 09:45AM  Rexahn Pharmaceuticals to Present Data on RX-3117 and Supinoxin(TM) at the 2015 American Association for Cancer Research Annual Meeting at noodls
09:10AM  Print at noodls
09:00AM  Rexahn Pharmaceuticals to Present Data on RX-3117 and Supinoxin(TM) at the 2015 American Association for Cancer Research Annual Meeting GlobeNewswire
Mar-20-15 10:26AM  UPDATE: MLV & Co Initiates Coverage On Rexahn Pharmaceuticals On Oncology Pipeline With Strategic Flexibility +6.55%
08:39AM  Coverage initiated on Rexahn Pharmaceuticals by MLV & Co
Mar-18-15 09:20AM  Rexahn Pharmaceuticals to Present at the 12th Annual BIO Asia International Conference in Tokyo, Japan at noodls
09:00AM  Rexahn Pharmaceuticals to Present at the 12th Annual BIO Asia International Conference in Tokyo, Japan GlobeNewswire
Mar-17-15 09:27AM  Rexahn Pharmaceuticals Reports Fourth Quarter and Full-Year 2014 Financial Results and Pipeline Update at noodls
09:00AM  Rexahn Pharmaceuticals Reports Fourth Quarter and Full-Year 2014 Financial Results and Pipeline Update GlobeNewswire
Mar-16-15 04:38PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
Mar-04-15 09:24AM  Rexahn Pharmaceuticals to Present at the BIO-Europe Spring(R) 2015 Conference in Paris, France at noodls
09:00AM  Rexahn Pharmaceuticals to Present at the BIO-Europe Spring(R) 2015 Conference in Paris, France GlobeNewswire
Mar-02-15 09:39AM  Rexahn Pharmaceuticals to Present at the ROTH Capital Partners 27th Annual Growth Stock Conference at noodls
Feb-18-15 09:32AM  Rexahn Pharmaceuticals to Present at the 3rd Annual Sachs Cancer Bio Partnering & Investment Forum in New York at noodls +6.49%
09:00AM  Rexahn Pharmaceuticals to Present at the 3rd Annual Sachs Cancer Bio Partnering & Investment Forum in New York GlobeNewswire
Feb-09-15 09:23AM  Rexahn Pharmaceuticals Announces the Publication of Preclinical Data for Supinoxin(TM) (RX-5902) Demonstrating Mechanism of Action at noodls
09:00AM  Rexahn Pharmaceuticals Announces the Publication of Preclinical Data for Supinoxin(TM) (RX-5902) Demonstrating Mechanism of Action GlobeNewswire
Feb-04-15 04:20PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
09:00AM  Rexahn Pharmaceuticals Announces the Appointment of Ely Benaim, M.D., as Chief Medical Officer GlobeNewswire
Feb-02-15 09:00AM  Rexahn Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference GlobeNewswire
Jan-07-15 09:00AM  Rexahn Pharmaceuticals to Present at Biotech Showcase(TM) 2015 GlobeNewswire +5.96%
Jan-06-15 09:00AM  Rexahn Pharmaceuticals Announces Publication of Preclinical Data for RX-3117 Demonstrating Effectiveness Against Gemcitabine Resistant Human Cancer Cells GlobeNewswire
Dec-10-14 05:46AM  Why Rexahn Pharmaceuticals (RNN) Could Be Positioned for a Surge? Zacks
Dec-09-14 07:39AM  Rexahn Pharmaceuticals, Inc. (RNN) Rises: Stock Up 8.6% Zacks
Dec-05-14 05:48AM  Rexahn Pharmaceuticals (RNN): Strong Industry, Solid Earnings Estimate Revisions Zacks
Dec-04-14 09:00AM  Rexahn Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 10, 2014 GlobeNewswire
Dec-03-14 04:19PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and EDGAR Online
09:00AM  Rexahn Pharmaceuticals Appoints Richard Rodgers to Its Board of Directors GlobeNewswire
Nov-17-14 09:00AM  Rexahn Pharmaceuticals to Participate in Brean Capital 2014 Life Sciences Summit GlobeNewswire
Nov-14-14 07:09PM  10-Q for Rexahn Pharmaceuticals, Inc. Company Spotlight
Nov-13-14 09:18AM  Rexahn posts 3Q loss AP
09:00AM  Rexahn Pharmaceuticals Reports Third Quarter 2014 Financial Results and Pipeline Update GlobeNewswire
Nov-12-14 04:33PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
Nov-11-14 09:00AM  Rexahn Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference on November 18, 2014 GlobeNewswire
Oct-28-14 09:00AM  Rexahn Pharmaceuticals to Present at the BIO-Europe(R) Conference in Frankfurt, Germany GlobeNewswire
Oct-03-14 04:24PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Financial Statements and Exhibits EDGAR Online
Sep-30-14 09:00AM  Rexahn Pharmaceuticals to Present at 13th Annual BIO Investor Forum GlobeNewswire
Sep-26-14 07:54AM  Rexahn Pharmaceuticals (RNN) Jumps: Stock Gains 10.2% Zacks
Sep-24-14 04:30PM  Rexahn Receives FDA Orphan Drug Designation for RX-3117 in Treatment of Pancreatic Cancer GlobeNewswire
Sep-23-14 09:00AM  Rexahn Pharmaceuticals to Present at the 14th Annual Biotech in Europe Investor Forum for Global Partnering and Investment in Basel, Switzerland GlobeNewswire
Sep-16-14 09:00AM  Rexahn Pharmaceuticals to Present at the BioPharm America 2014 in Boston, Massachusetts, USA Business Wire
Sep-04-14 09:00AM  Rexahn Pharmaceuticals to Present at the 16th Annual Rodman & Renshaw Global Investment Conference on September 9, 2014 Business Wire +7.79%
06:48AM  Rexahn Pharmaceuticals (RNN) Jumps: Stock Rises 9.6% Zacks
Sep-03-14 09:00AM  Rexahn Receives a Notice of Allowance from the U.S. Patent and Trademark Office for a Novel Targeted Cancer Drug Delivery Platform Business Wire +10.00%
Aug-14-14 09:00AM  Rexahn Pharmaceuticals Reports Second Quarter 2014 Financial Results and Pipeline Update Business Wire -5.48%
Aug-13-14 04:33PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
Jul-18-14 09:00AM  Rexahn Pharmaceuticals Provides Update on Phase I Supinoxin Trial in Cancer Patients with Solid Tumors Business Wire
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer and other medical needs. The company has three clinical stage oncology candidates: Archexin, RX-3117, and Supinoxin (RX-5902), as well as a pipeline of preclinical compounds to treat multiple types of cancer. It has also developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES. Rexahn Pharmaceuticals, Inc. is based in Rockville, Maryland.